These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36824056)

  • 21. Measurable Residual Disease in Chronic Lymphocytic Leukemia: Current Understanding and Evolving Role in Clinical Practice.
    Rios-Olais FA; Hilal T
    Curr Treat Options Oncol; 2023 Aug; 24(8):907-928. PubMed ID: 37195588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MAGIC-DR: An interpretable machine-learning guided approach for acute myeloid leukemia measurable residual disease analysis.
    Shopsowitz K; Lofroth J; Chan G; Kim J; Rana M; Brinkman R; Weng A; Medvedev N; Wang X
    Cytometry B Clin Cytom; 2024 Jul; 106(4):239-251. PubMed ID: 38415807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.
    Reiter M; Diem M; Schumich A; Maurer-Granofszky M; Karawajew L; Rossi JG; Ratei R; Groeneveld-Krentz S; Sajaroff EO; Suhendra S; Kampel M; Dworzak MN;
    Cytometry A; 2019 Sep; 95(9):966-975. PubMed ID: 31282025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study.
    Rawstron AC; Fazi C; Agathangelidis A; Villamor N; Letestu R; Nomdedeu J; Palacio C; Stehlikova O; Kreuzer KA; Liptrot S; O'Brien D; de Tute RM; Marinov I; Hauwel M; Spacek M; Dobber J; Kater AP; Gambell P; Soosapilla A; Lozanski G; Brachtl G; Lin K; Boysen J; Hanson C; Jorgensen JL; Stetler-Stevenson M; Yuan C; Broome HE; Rassenti L; Craig F; Delgado J; Moreno C; Bosch F; Egle A; Doubek M; Pospisilova S; Mulligan S; Westerman D; Sanders CM; Emerson R; Robins HS; Kirsch I; Shanafelt T; Pettitt A; Kipps TJ; Wierda WG; Cymbalista F; Hallek M; Hillmen P; Montserrat E; Ghia P
    Leukemia; 2016 Apr; 30(4):929-36. PubMed ID: 26639181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group.
    Kovacs G; Robrecht S; Fink AM; Bahlo J; Cramer P; von Tresckow J; Maurer C; Langerbeins P; Fingerle-Rowson G; Ritgen M; Kneba M; Döhner H; Stilgenbauer S; Klapper W; Wendtner CM; Fischer K; Hallek M; Eichhorst B; Böttcher S
    J Clin Oncol; 2016 Nov; 34(31):3758-3765. PubMed ID: 27573660
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurable residual disease in the treatment of chronic lymphocytic leukemia.
    Uchiyama T; Yokoyama A; Aoki S
    J Clin Exp Hematop; 2020 Dec; 60(4):138-145. PubMed ID: 33148932
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial.
    Böttcher S; Ritgen M; Fischer K; Stilgenbauer S; Busch RM; Fingerle-Rowson G; Fink AM; Bühler A; Zenz T; Wenger MK; Mendila M; Wendtner CM; Eichhorst BF; Döhner H; Hallek MJ; Kneba M
    J Clin Oncol; 2012 Mar; 30(9):980-8. PubMed ID: 22331940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment.
    Logan AC; Gao H; Wang C; Sahaf B; Jones CD; Marshall EL; Buño I; Armstrong R; Fire AZ; Weinberg KI; Mindrinos M; Zehnder JL; Boyd SD; Xiao W; Davis RW; Miklos DB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(52):21194-9. PubMed ID: 22160699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Machine learning optimized multiparameter radar plots for B-cell acute lymphoblastic leukemia minimal residual disease analysis.
    Shopsowitz KE; Liu L; Setiadi A; Al-Bakri M; Vercauteren S
    Cytometry B Clin Cytom; 2022 Sep; 102(5):342-352. PubMed ID: 35726954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD79b expression in B cell chronic lymphocytic leukemia: its implication for minimal residual disease detection.
    Garcia Vela J; Delgado I; Benito L; Monteserin M; Garcia Alonso L; Somolinos N; Andreu M; Oña F
    Leukemia; 1999 Oct; 13(10):1501-5. PubMed ID: 10516749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.
    Farren TW; Giustiniani J; Fanous M; Liu F; Macey MG; Wright F; Prentice A; Nathwani A; Agrawal SG
    Blood Cancer J; 2015 Jan; 5(1):e273. PubMed ID: 25615279
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Identification of critical hemodilution by artificial intelligence in bone marrow assessed for minimal residual disease analysis in acute myeloid leukemia: The Cinderella method.
    Hoffmann J; Thrun MC; Röhnert MA; von Bonin M; Oelschlägel U; Neubauer A; Ultsch A; Brendel C
    Cytometry A; 2023 Apr; 103(4):304-312. PubMed ID: 36030398
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Minimal residual disease monitoring in chronic lymphocytic leukaemia patients. A comparative analysis of flow cytometry and ASO IgH RQ-PCR.
    Raponi S; Della Starza I; De Propris MS; Del Giudice I; Mauro FR; Marinelli M; Di Maio V; Piciocchi A; Foà R; Guarini A
    Br J Haematol; 2014 Aug; 166(3):360-8. PubMed ID: 24735016
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurable residual disease in adult acute myeloid leukaemia: evaluation of a multidimensional 'radar' flow cytometric plot analysis method.
    van der Linde R; Smith S; Brown DA; Sasson SC; Tegg E
    Pathology; 2023 Apr; 55(3):383-390. PubMed ID: 36725446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early (Day 15 Post Diagnosis) Peripheral Blood Assessment of Measurable Residual Disease in Flow Cytometry is a Strong Predictor of Outcome in Childhood B-Lineage Lymphoblastic Leukemia.
    Loosveld M; Nivaggioni V; Arnoux I; Bernot D; Michel G; Béné MC; Eveillard M
    Cytometry B Clin Cytom; 2019 Mar; 96(2):128-133. PubMed ID: 30734503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinically validated machine learning algorithm for detecting residual diseases with multicolor flow cytometry analysis in acute myeloid leukemia and myelodysplastic syndrome.
    Ko BS; Wang YF; Li JL; Li CC; Weng PF; Hsu SC; Hou HA; Huang HH; Yao M; Lin CT; Liu JH; Tsai CH; Huang TC; Wu SJ; Huang SY; Chou WC; Tien HF; Lee CC; Tang JL
    EBioMedicine; 2018 Nov; 37():91-100. PubMed ID: 30361063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia.
    Davydova Y; Galtseva I; Kapranov N; Nikiforova K; Aleshina O; Chabaeva Y; Isinova G; Kotova E; Sokolov A; Troitskaya V; Kulikov S; Parovichnikova E
    Diagnostics (Basel); 2022 Dec; 13(1):. PubMed ID: 36611312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
    Fürstenau M; Weiss J; Giza A; Franzen F; Robrecht S; Fink AM; Fischer K; Schneider C; Tausch E; Stilgenbauer S; Ritgen M; Schilhabel A; Brüggemann M; Eichhorst B; Hallek M; Cramer P
    Clin Cancer Res; 2022 Oct; 28(19):4203-4211. PubMed ID: 35594173
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.
    Moreton P; Kennedy B; Lucas G; Leach M; Rassam SM; Haynes A; Tighe J; Oscier D; Fegan C; Rawstron A; Hillmen P
    J Clin Oncol; 2005 May; 23(13):2971-9. PubMed ID: 15738539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is there an impact of measurable residual disease as assessed by multiparameter flow cytometry on survival of AML patients treated in clinical practice? A population-based study.
    Rosso A; Juliusson G; Lorenz F; Lehmann S; Derolf Å; Deneberg S; Jädersten M; Antunovic P; Cammenga J; Möllgård L; Wennström L; Ölander E; Ehinger M; Fogelstrand L; Höglund M; Lazarevic VL
    Leuk Lymphoma; 2021 Aug; 62(8):1973-1981. PubMed ID: 33719843
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.